Published on 21/12/2025

How to Use Site Readiness Checklists for Site Initiation Visits

Before any clinical site is activated for patient enrollment, it must demonstrate full operational readiness during the Site Initiation Visit (SIV). A well-designed site readiness checklist serves as a critical quality assurance tool that enables Clinical Research Associates (CRAs), sponsors, and site staff to verify that all regulatory, logistical, and procedural components are in place. This tutorial provides a step-by-step approach to building and using site readiness checklists effectively to streamline trial startup and support audit preparedness.

Table of Contents

Why a Site Readiness Checklist Is Essential

Without a structured checklist, critical steps may be missed, such as:

Regulatory approvals not in place
Untrained site staff handling study procedures
Investigational product (IP) storage non-compliant with specifications
Missing essential documents in the Investigator Site File (ISF)

A checklist standardizes site evaluation and ensures consistent practices across all clinical trial sites in compliance with USFDA and EMA guidelines.

Key Components of a Site Readiness Checklist

The checklist should be divided into the following categories, each encompassing critical startup elements:

1. Regulatory Documentation

IRB/EC approval letter for protocol and ICF
Signed and dated 1572 or country-specific equivalent
GCP certificates for all site personnel
Curricula vitae (CVs) of the PI and Sub-Is
Delegation of Authority Log

2. Site

Staff Training

Protocol-specific training completed and documented
System training (EDC, IWRS, ePRO) completed
IP accountability and storage training provided

3. Investigational Product Management

Temperature-controlled storage verified with backup monitoring
Drug Accountability Logs available and prepared
Unblinding procedures understood by PI
Receipt of IP shipment documented

4. Equipment and Facility Readiness

Calibrated equipment (centrifuges, ECG machines, etc.)
Lab kits and sample processing supplies received
Secure and locked storage for documents and IP
Environmental controls in place and monitored

5. Site Personnel and Communication

Staff roles and responsibilities clearly documented
Contact list shared with sponsor and updated
CRA and site staff communication plan agreed
Escalation procedures defined

6. Source Documentation and ISF Review

Source templates approved and filed
Investigator Site File (ISF) organized with version control
Pre-screening logs available (if applicable)
Checklists signed by CRA and PI

Ensure that all components follow the relevant GMP documentation and Good Clinical Practice (GCP) principles.

Store this template in editable format at both the CRA and site end, and file a scanned signed version in the Trial Master File (TMF).

When to Use the Checklist

Before and during the SIV to assess readiness
After SIV as part of the activation approval process
Before subject screening begins
Prior to audits or inspections for readiness validation

Best Practices

Customize the checklist for study phase and therapeutic area
Review each checklist item with the site in real time
Use digital platforms for version control and signoff
Include a section for CRA observations and site action items
Cross-reference with Stability Studies templates for validation readiness

CRA Responsibilities

Ensure checklist completion before site activation
Flag missing items in the SIV Follow-Up Letter
Verify all documents filed in ISF and TMF
Obtain PI and CRA signatures on final checklist

Conclusion

A site readiness checklist is a cornerstone of clinical trial startup success. It enables CRAs and sponsors to ensure that nothing is overlooked and that each site meets all operational, regulatory, and protocol-specific requirements. By leveraging structured checklists, sponsors can reduce the risk of protocol deviations, site delays, and regulatory findings—ultimately ensuring a faster and safer path to study completion.